Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis. Issue 10 (8th October 2017)

• Record Type: Journal Article
• Authors: Keane, Kevin N; Yovich, John L; Hamidi, Anahita; Hinchliffe, Peter M; Dhaliwal, Satvinder S
• Is Part Of: BMJ open. Volume 7:Issue 10(2017)
• Publication Date: 2017-10-08
• Subjects: adjuvants -- embryo quality -- in vitro fertilisation; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2017-018107
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Background: Patients undergoing in vitro fertilisation (IVF) receive various adjuvant therapies in order to enhance success rates, but the true benefit is actively debated. Growth hormone (GH) supplementation was assessed in poor-prognosis women undergoing fresh IVF transfer cycles. Methods: Data were retrospectively analysed from 400 IVF cycles, where 161 women received GH and 239 did not. Results: Clinical pregnancy, live birth rates and corresponding ORs and CIs were significantly greater with GH, despite patients being significantly older with lower ovarian reserve. Patient's age, quality of transferred embryo and GH were the only significant independent predictors of clinical pregnancy (OR: 0.90, 5.00 and 2.49, p<0.002, respectively) and live birth chance (OR: 0.91, 3.90 and 4.75, p<0.014, respectively). GH increased clinical pregnancy chance by 3.42-fold (95% CI 1.82 to 6.44, p<0.0005) and live birth chance by 6.16-fold (95% CI 2.83 to 13.39, p<0.0005) after adjustment for maternal age, antral follicle count and transferred embryo quality. Conclusion: These data provided further evidence to indicate that GH may support more live births, particularly in younger women. It also appears that embryos generated under GH have a better implantation potential, but whether the biological mechanism is embryo-mediated or endometrium-mediated is unclear.